TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

IN8bio Reports Third Quarter 2025 Financial Results and Recent Business Highlights

GlobeNewswire Inc. Logo GlobeNewswire Inc. By In8Bio, Inc.
IN8bio Reports Third Quarter 2025 Financial Results and Recent Business Highlights

IN8bio reported financial results and highlighted preclinical data on INB-619, a novel gamma-delta T cell engager, demonstrating potential for deep B cell depletion with minimal adverse effects. The company expanded its INB-100 Phase 1 clinical trial to The Ohio State University and continues advancing its T cell therapy platform.

Insights
MSFT   neutral

Mentioned as a cloud computing competitor with 20% market share


INAB   positive

Company showed promising preclinical data, expanded clinical trial, reduced expenses, and maintained a strategic focus on developing innovative T cell therapies